Lupin announced the sale of its US commercial women’s health specialty business, focusing on Solosec, to Evofem Biosciences. Solosec, an FDA-approved single-dose treatment for bacterial vaginosis and trichomoniasis, is the key product involved. The deal includes potential payments up to USD 84 million based on future milestones.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/d1Gyk7c
via IFTTT
Home »
Healthcare/Biotech-Industry-Economic Times
» Lupin divests women's health specialty business in US to Evofem Biosciences for nearly $84 mn
0 comments:
Post a Comment